secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001628280-23-033033
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia: Vafseo approved in Australia; Auryxia 2023 revenue guidance lowered to $170-175M
--------------------------------------------------------------------------------

- Australia's TGA approved Vafseo (vadadustat) for anemia in dialysis patients; product now approved in 35 countries.
- Akebia lowered Auryxia net product revenue guidance for 2023 to $170-175M from $175-180M due to market dynamics.
- Company plans to resubmit U.S. NDA for vadadustat by end of Q3 2023.
- Appointed Graham Ray (ex-Takeda) as VP, Key Accounts to lead U.S. launch prep and customer engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/0001628280-23-033033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000162828023033033/akba-20230926.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-033033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer